 |
|
| Dear %%Firstname%%, |
|
| Antibody-Drug Conjugates (ADC) |
|
| ADCs have evolved since the initial approval of MYLOTARG® in 2000, with respect to conjugation, linker and toxin chemistries and processing. With the current availability of 4 commercially approved drugs and approximately 80 programs in various clinical trials, there has been a significant interest in simplifying the complex supply chain. With approximately 80% of the programs outsourced to Contract Development and Manufacturing Organizations (CDMOs), a transparent and integrated supply chain is critical for the success of ADC projects. |
|
| Learn more about:
|
|
| • |
How ADC manufacturing has evolved over the past decade |
|
| • |
The challenges that this evolution implies |
|
| • |
Why an integrated supply chain has become increasingly important for the success of ADC projects |
|
|
|
|
|
|
 |
|
| MilliporeSigma offers a comprehensive portfolio of products and services for ADC manufacturing. |
|
| If you would like to learn more about the ADC solutions that MilliporeSigma/Merck provides, click here
|
|
|
|
|
|
